Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary) ; CD26 antigen inhibitors; Glucagon-like peptide 1 agonist; Insulin; Sulfonylureas; Thiazolidinediones
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EASEL
- Sponsors Janssen Research & Development
- 17 Nov 2017 Primary endpoint has been met. (Incidence Rate of the Composite of All-cause Mortality (ACM) or Hospitalization for Heart Failure (HF)), according to a Janssen Pharmaceuticals media release.
- 17 Nov 2017 Results of retrospective analysis presented in a Janssen Pharmaceuticals media release.
- 17 Nov 2017 Status changed from active, no longer recruiting to completed.